Drug Trial Radar · NCT01506141
An Extension Study of HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Idursulfase-IT in Conjunction With Elaprase in Pediatric Participants With Hunter Syndrome and Cognitive Impairment
Last checked: Nov 20, 2026Latest source record: Aug 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
15
Actual
Start
Aug 1, 2010
Primary completion
Apr 30, 2024
Study completion Apr 30, 2024
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Jan 9, 2012
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 3 years, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This extension study of HGT-HIT-045 is designed to collect long-term safety data in pediatric participants with Hunter syndrome and cognitive impairment who are receiving intrathecal (IT) idursulfase-IT and intravenous (IV) Elaprase enzyme replacement therapy.
Conditions
- Hunter Syndrome
Interventions
Idursulfase-ITDrug
Idursulfase-IT once monthly via IDDD.
ElapraseDrug
Weekly IV infusions of commercially available Elaprase.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-emergent Adverse Events (TEAEs)Time frame: From start of study drug administration up to follow-up (up to 165 months)
- Number of Participants With Clinically Significant Changes or Apparent Difference Across Treatment Groups in Laboratory ParametersTime frame: From start of study drug administration up to follow-up (up to 165 months)
- Number of Participants With Clinically Significant Changes or Apparent Difference Across Treatment Groups in 12-lead Electrocardiogram (ECG) FindingsTime frame: From start of study drug administration up to follow-up (up to 165 months)
- CSF Chemistries: Change From Baseline in CSF Total Cell CountTime frame: Baseline, Month 163
- CSF Chemistries: Change From Baseline in CSF GlucoseTime frame: Baseline, Month 163
- CSF Chemistries: Change From Baseline in CSF ProteinTime frame: Baseline, Month 163
- Number of Participants With Anti-idursulfase Antibodies in CSFTime frame: From start of study drug administration up to follow-up (up to 165 months)
- Number of Participants With Anti-idursulfase Antibodies in SerumTime frame: From start of study drug administration up to follow-up (up to 165 months)
Locations
9 sites in 3 countries. Site status is shown where the registry gives one.
Ann & Robert H Lurie Childrens Hospital of Chicago
Chicago, Illinois
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
Legacy Emanuel Hospital
Portland, Oregon
Children's Hospital of Pittsburgh of UPMC
Pittsburgh, Pennsylvania
Vanderbilt Children's Hospital
Nashville, Tennessee
University of Utah Hospital
Salt Lake City, Utah
Seattle Children's Hospital
Seattle, Washington
British Columbia Children's Hospital
Vancouver, British Columbia, Canada
Birmingham Children's Hospital
Birmingham, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.